OTCMKTS:HKMPF

Hikma Pharmaceuticals - HKMPF Stock Forecast, Price & News

$18.23

0.00 (0.00%)

(As of 12/1/2022 12:00 AM ET)

Add

Compare

Today's Range: $18.23
▼
$18.23
50-Day Range: $13.76
▼
$18.23
52-Week Range: $13.76
▼
$29.24

Volume: N/A
Average Volume: 75 shs
Market Capitalization: $4.01 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About Hikma Pharmaceuticals (OTCMKTS:HKMPF) Stock

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Receive HKMPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HKMPF Stock News Headlines

November 5, 2022 | benzinga.com

Hikma Pharmaceuticals Stock (OTC:HKMPF), Earnings Estimates, EPS, and Revenue

September 20, 2022 | finance.yahoo.com

Could The Market Be Wrong About Hikma Pharmaceuticals PLC (LON:HIK) Given Its Attractive Financial Prospects?

September 10, 2022 | seekingalpha.com

HKMPF Hikma Pharmaceuticals PLC

September 9, 2022 | morningstar.com

Hikma Pharmaceuticals PLC HKMPF Stock Chart

August 5, 2022 | seekingalpha.com

Hikma Pharmaceuticals PLC 2022 Q2 - Results - Earnings Call Presentation

August 4, 2022 | proactiveinvestors.com

Hikma Pharma slides on lower generics guidance

August 4, 2022 | marketwatch.com

Hikma Pharmaceuticals Plc 1H Rev $1.21B

June 10, 2022 | finance.yahoo.com

Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 32% Above Their Intrinsic Value Estimate

May 24, 2022 | markets.businessinsider.com

Hikma Pharma CEO Siggi Olafsson Resigns - Quick Facts

May 5, 2022 | proactiveinvestors.com.au

FTSE 100 soars after Wall St 'relief rally' and ahead of Bank of England decision but Hikma drops

April 29, 2022 | finanznachrichten.de

Hikma Pharmaceuticals PLC: Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals

April 25, 2022 | marketwatch.com

Hikma Pharmaceuticals Gets Low Support for Re-Election of Patrick Butler at AGM

April 20, 2022 | proactiveinvestors.com.au

FTSE 100 flat but Wall Street makes a positive start despite Netflix flop

April 13, 2022 | finance.yahoo.com

Cross River Announces Completion of Inaugural Drill Campaign at the McVicar Gold Project, NW Ontario

April 13, 2022 | finance.yahoo.com

Is Hikma Pharmaceuticals PLC's (LON:HIK) Stock's Recent Performance A Reflection Of Its Financial Health?

March 29, 2022 | finance.yahoo.com

Hikma Ventures invests in Tact.ai, an AI-powered customer engagement platform for life sciences companies

February 24, 2022 | marketwatch.com

Hikma Pharmaceutical FY EPS $1.807

February 24, 2022 | markets.businessinsider.com

Hikma Pharma FY21 Profit Down, Lifts Dividend; Stock Down

February 24, 2022 | proactiveinvestors.com

Hikma Pharmaceuticals sales grow 9%, announces US$300mln share buyback

February 24, 2022 | proactiveinvestors.com

Hikma Pharmaceuticals annual sales grow 9% but Generics guidance fails to meet expectations

February 19, 2022 | uk.finance.yahoo.com

2 cheap UK stocks to buy for the rotation into value

December 15, 2021 | finance.yahoo.com

Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 45% Discount?

September 27, 2021 | marketwatch.com

Hikma Pharmaceuticals Agrees to Buy Custopharm Inc. For $375 Mln

September 20, 2021 | finance.yahoo.com

Hikma and FAES Farma enter into exclusive licensing agreement for the commercialisation of Bilastine tablets in the US

August 7, 2021 | marketwatch.com

Hikma Pharmaceuticals 1H Rev $1.22B

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive HKMPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HKMPF Company Calendar

Today: 12/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Private households
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:HKMPF
Previous Symbol: OTC:HKMPF
CUSIP: N/A
CIK: N/A
Web: www.hikma.com
Phone: 442073992760
Fax: 44-20-7399-2761
Employees: 8,700
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $2.55 billion
Price / Sales: 1.57
Cash Flow: $3.07 per share
Price / Cash Flow: 5.94
Book Value: $10.18 per share
Price / Book: 1.79

Miscellaneous

Outstanding Shares: 220,230,000
Free Float: N/A
Market Cap: $4.01 billion
Optionable: Not Optionable
Beta: 0.52

Key Executives

Engineer Said Samih Taleb Darwazah (Age 65)
Exec. Chairman & CEO
Comp: $2.71M

Mr. Mazen Samih Taleb Darwazah (Age 64)
Exec. Vice Chairman & Pres of MENA
Comp: $2.11M

Mr. Khalid Waleed Hosny Al Nabilsi (Age 50)
Chief Financial Officer

Mr. Hussein Arkhagha
Company Sec. & Chief Counsel

Mr. Bassam Wael Rushdi Kanaan CFA (Age 57)
CPA, Exec. VP of Corp. Devel. and M&A

Ms. Susan Ringdal
Exec. VP of Strategic Planning & Global Affairs

Ms. Majda Labadi
Exec. VP of Organisational Devel.

Mr. Riad Mishlawi
Pres of Injectables

Mr. Brian Hoffmann
Pres of Generics

Mr. Samuel Park
Global Head of Intellectual Property (IP) & Gen. Counsel for US

Key Competitors

View All Competitors

HKMPF Stock - Frequently Asked Questions

Should I buy or sell Hikma Pharmaceuticals stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HKMPF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HKMPF, but not buy additional shares or sell existing shares.
View HKMPF analyst ratings or view top-rated stocks.
How have HKMPF shares performed in 2022?: Hikma Pharmaceuticals' stock was trading at $28.64 at the start of the year. Since then, HKMPF shares have decreased by 36.3% and is now trading at $18.23.
View the best growth stocks for 2022 here.
What is Hikma Pharmaceuticals' stock symbol?: Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPF."

How do I buy shares of Hikma Pharmaceuticals?: Shares of HKMPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Hikma Pharmaceuticals' stock price today?: One share of HKMPF stock can currently be purchased for approximately $18.23.
How much money does Hikma Pharmaceuticals make?: Hikma Pharmaceuticals (OTCMKTS:HKMPF) has a market capitalization of $4.01 billion and generates $2.55 billion in revenue each year.
How many employees does Hikma Pharmaceuticals have?: The company employs 8,700 workers across the globe.
How can I contact Hikma Pharmaceuticals?: Hikma Pharmaceuticals' mailing address is 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR. The official website for the company is www.hikma.com. The company can be reached via phone at 442073992760, via email at investors@hikma.uk.com, or via fax at 44-20-7399-2761.

This page (OTCMKTS:HKMPF) was last updated on 12/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial